4.7 Article

Effect of Raloxifene on Stroke and Venous Thromboembolism According to Subgroups in Postmenopausal Women at Increased Risk of Coronary Heart Disease

期刊

STROKE
卷 40, 期 1, 页码 147-155

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.108.518621

关键词

clinical trial; stroke; venous thromboembolism

资金

  1. Eli Lilly and Company, Indianapolis, Ind
  2. NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K24HL076346] Funding Source: NIH RePORTER

向作者/读者索取更多资源

Background and Purpose-Raloxifene, a selective estrogen receptor modulator, reduces risk of invasive breast cancer and osteoporosis, but the effect on risk for stroke and venous thromboembolism in different patient subgroups is not established. The purpose of this analysis was to evaluate the effect of raloxifene on the incidence of all strokes, stroke deaths, and venous thromboembolic events according to participant subgroups. Methods-This was a secondary end point analysis of an international, randomized, placebo-controlled clinical trial of 10 101 postmenopausal women with or at increased risk of coronary heart disease followed a median of 5.6 years. Strokes, venous thromboembolic events, and deaths were adjudicated by expert centralized committees. Strokes were categorized as ischemic, hemorrhagic, or undetermined and venous thromboembolic events were subclassified. Results-The incidences of all strokes did not differ between raloxifene (incidence rate per 100 woman-years = 0.95) and placebo (incidence rate = 0.86) treatment groups (P = 0.30). In women assigned raloxifene versus placebo, there was a higher incidence of fatal strokes (incidence rates = 0.22 and 0.15, respectively, P = 0.0499) and venous thromboembolic events (incidence rates = 0.39 and 0.27, respectively, P = 0.02). No significant subgroup interactions were found except that there was a higher incidence of stroke associated with raloxifene use among current smokers. Conclusions-In postmenopausal women at increased risk for coronary events, the incidences of venous thromboembolism and fatal stroke but not all strokes were higher in those assigned raloxifene versus placebo. Raloxifene's effect did not differ across subgroups, except that the risk of stroke differed by smoking status. Treatment decisions about raloxifene should be based on a balance of projected absolute risks and benefits. (Stroke. 2009; 40: 147-155.)

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据